[go: up one dir, main page]

CL2004000647A1 - Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am - Google Patents

Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Info

Publication number
CL2004000647A1
CL2004000647A1 CL200400647A CL2004000647A CL2004000647A1 CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1 CL 200400647 A CL200400647 A CL 200400647A CL 2004000647 A CL2004000647 A CL 2004000647A CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1
Authority
CL
Chile
Prior art keywords
inhibitors
amiloid
beta
angiopatia
heterocicles
Prior art date
Application number
CL200400647A
Other languages
English (en)
Inventor
Anthony Frank Resnick Ly Kreft
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2004000647A1 publication Critical patent/CL2004000647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON COMPUESTOS FLUORO Y TRIFLUOROALQUILO QUE CONTIENEN INHIBIDORES DE SULFONAMIDAS HETEROCICLICOCS DE BETA AMILOIDES SU METODO DE PRODUCCION Y SUS DERIVADOS DE LOS MISMOS Y LOS METODOS DE TRATAMIENTOS QUE LOS EMPLEAN. PARTICULARMENTE, LOS INHIBIDORES UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.
CL200400647A 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am CL2004000647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31

Publications (1)

Publication Number Publication Date
CL2004000647A1 true CL2004000647A1 (es) 2005-02-04

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400647A CL2004000647A1 (es) 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Country Status (22)

Country Link
US (3) US7300951B2 (es)
EP (1) EP1608638A1 (es)
JP (1) JP2006522126A (es)
KR (1) KR20060002908A (es)
CN (2) CN101274926A (es)
AR (1) AR043940A1 (es)
AU (1) AU2004230844B2 (es)
BR (1) BRPI0408962A (es)
CA (1) CA2517155A1 (es)
CL (1) CL2004000647A1 (es)
CO (1) CO5640049A2 (es)
CR (1) CR7951A (es)
EC (1) ECSP056128A (es)
MX (1) MXPA05010368A (es)
NO (1) NO20054263L (es)
NZ (1) NZ542468A (es)
RU (1) RU2342374C2 (es)
SG (1) SG167669A1 (es)
TW (1) TWI336698B (es)
UA (1) UA82093C2 (es)
WO (1) WO2004092155A1 (es)
ZA (1) ZA200507896B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE330950T1 (de) * 2000-12-13 2006-07-15 Wyeth Corp Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion
HUP0500173A3 (en) * 2001-12-20 2009-03-30 Bristol Myers Squibb Co Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
PL374501A1 (en) * 2002-06-11 2005-10-31 Wyeth Substituted phenylsulfonamide inhibitors of beta amyloid production
MXPA05010368A (es) * 2003-03-31 2005-11-17 Wyeth Corp Sulfonamidas heterociclicas que contienen fluor- y trifluoroalquilo como inhibidores de la produccion beta amiloide y derivados de las mismas.
ATE443701T1 (de) * 2004-01-16 2009-10-15 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
AU2007217965A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
WO2007127108A1 (en) * 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
US20080233132A1 (en) * 2006-11-03 2008-09-25 Miller Stephen D Multiple sclerosis therapy
PE20090445A1 (es) * 2007-07-16 2009-05-18 Wyeth Corp Inhibidores de produccion de beta amiloide
AR067534A1 (es) * 2007-07-16 2009-10-14 Wyeth Corp Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas
PE20090810A1 (es) * 2007-07-16 2009-07-20 Wyeth Corp Procesos e intermediarios para la preparacion de compuestos de sulfonamida heterociclica
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2009089237A1 (en) * 2008-01-11 2009-07-16 Wyeth Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as beta-amyloid inhibitors
JP2011523633A (ja) * 2008-05-08 2011-08-18 ブリストル−マイヤーズ スクイブ カンパニー ２−アリールグリシンアミド誘導体
WO2010025968A2 (en) * 2008-09-05 2010-03-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223217B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
EP2544535B1 (en) 2010-03-10 2017-04-19 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
CN104869987B (zh) 2012-09-07 2020-10-16 麻省眼耳医院 用于再生毛细胞和/或支持细胞的方法及组合物
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
KR920019763A (ko) 1991-04-26 1992-11-19 모리다 가즈라 아졸 화합물, 그의 제조방법 및 용도
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
EP0910564B1 (en) 1995-11-28 2007-10-31 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
CN1238688A (zh) 1996-07-22 1999-12-15 孟山都公司 硫羟磺酰胺金属蛋白酶抑制剂
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
EP0942923A2 (en) 1996-11-22 1999-09-22 Elan Pharmaceuticals, Inc. N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
DE19650196A1 (de) 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6495578B1 (en) 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1218377A1 (en) 1999-10-08 2002-07-03 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
ATE346039T1 (de) 2000-03-20 2006-12-15 Merck Sharp & Dohme Sulfonamido-substituierte verbrückte bicycloalkylderivative
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
ATE330950T1 (de) 2000-12-13 2006-07-15 Wyeth Corp Heterocyclische sulfonamide als inhibitoren der beta-amyloid-produktion
CN1602290B (zh) 2001-12-11 2010-10-27 惠氏公司 制备手性纯的β-氨基醇的方法
WO2003050062A2 (en) 2001-12-11 2003-06-19 Wyeth PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS
PL374501A1 (en) 2002-06-11 2005-10-31 Wyeth Substituted phenylsulfonamide inhibitors of beta amyloid production
MXPA05010368A (es) 2003-03-31 2005-11-17 Wyeth Corp Sulfonamidas heterociclicas que contienen fluor- y trifluoroalquilo como inhibidores de la produccion beta amiloide y derivados de las mismas.
ATE443701T1 (de) 2004-01-16 2009-10-15 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
AU2007217965A1 (en) 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
RU2008131051A (ru) 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
US7476762B2 (en) 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
WO2007127108A1 (en) 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US7550629B2 (en) 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
PE20090810A1 (es) 2007-07-16 2009-07-20 Wyeth Corp Procesos e intermediarios para la preparacion de compuestos de sulfonamida heterociclica
PE20090445A1 (es) 2007-07-16 2009-05-18 Wyeth Corp Inhibidores de produccion de beta amiloide
AR067534A1 (es) 2007-07-16 2009-10-14 Wyeth Corp Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas

Also Published As

Publication number Publication date
RU2342374C2 (ru) 2008-12-27
BRPI0408962A (pt) 2006-04-04
CA2517155A1 (en) 2004-10-28
SG167669A1 (en) 2011-01-28
CO5640049A2 (es) 2006-05-31
US20040198778A1 (en) 2004-10-07
TWI336698B (en) 2011-02-01
NZ542468A (en) 2009-01-31
ZA200507896B (en) 2007-03-28
US20070254929A1 (en) 2007-11-01
MXPA05010368A (es) 2005-11-17
CN1780829A (zh) 2006-05-31
UA82093C2 (uk) 2008-03-11
CR7951A (es) 2008-10-29
ECSP056128A (es) 2006-03-01
NO20054263L (no) 2005-12-14
NO20054263D0 (no) 2005-09-15
AR043940A1 (es) 2005-08-17
US7300951B2 (en) 2007-11-27
TW200504047A (en) 2005-02-01
AU2004230844A1 (en) 2004-10-28
US7858658B2 (en) 2010-12-28
RU2005133434A (ru) 2006-07-10
US20090227667A1 (en) 2009-09-10
US7547725B2 (en) 2009-06-16
EP1608638A1 (en) 2005-12-28
WO2004092155A1 (en) 2004-10-28
AU2004230844B2 (en) 2010-12-09
JP2006522126A (ja) 2006-09-28
KR20060002908A (ko) 2006-01-09
CN101274926A (zh) 2008-10-01
CN1780829B (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.